共 408 条
[1]
Smolen J(2016)Rheumatoid arthritis Lancet 388 2023-2038
[2]
Aletaha D(2015)Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis Rheumatol Int 35 1693-1699
[3]
McInnes I(2005)Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis Arthritis Res Ther 7 R949-958
[4]
Katchamart W(2020)Association of Seropositivity and Mortality in Rheumatoid Arthritis and the Impact of Treatment With Disease-Modifying Antirheumatic Drugs: Results From a Real-World Study Arthritis Care Res (Hoboken) 72 176-183
[5]
Koolvisoot A(2010)2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative Arthritis Rheum 62 2569-2581
[6]
Aromdee E(2021)2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis Arthritis Rheumatol 73 1108-1123
[7]
Chiowchanwesawakit P(2020)EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update Ann Rheum Dis 79 685-699
[8]
Muengchan C(2017)The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting Nat Rev Immunol 17 60-75
[9]
van der Helm-van Mil AHM(2008)Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy Ann Rheum Dis 67 547-554
[10]
Verpoort KN(2014)Longterm safety, efficacy, and inhibition of structural damage progression over 5 years of treatment with abatacept in patients with rheumatoid arthritis in the abatacept in inadequate responders to methotrexate trial J Rheumatol 41 1077-1087